Login to Your Account

Antidepressant GLYX-13 Shows Promise in Phase IIa

By Marie Powers
Staff Writer

Thursday, December 6, 2012
Privately held Naurex Inc. posted impressive Phase IIa results for lead antidepressant compound, GLYX-13, a partial agonist of the N-Methyl-D-Aspartate (NMDA) receptor, showing statistically significant reductions in depression scores in patients who had failed treatment with one or more antidepressant agents.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription